Lynn Seely

Lynn Seely is President & Chief Executive Officer at Lyell Immunopharma, Inc. since 2026.
Dr. Seely is Independent Director at AbCellera Biologics, Inc. starting in 2026.
Dr. Seely is Member-Managers Board at Life Science Cares Bay Area.
Former roles include Chief Executive Officer at Myovant Sciences, Inc. from 2019 to 2020.
President, Chief Executive Officer & Director at Myovant Sciences Ltd. from 2016 to 2021.
Associate Director-Clinical Development at Chiron Corp.
from 1996 to 2000.
Lead Independent Director at Blueprint Medicines Corp.
from 2016 to 2025.
Director at Roivant Sciences GmbH.
Chief Medical Officer at Orion Acquisition Corp.
II in 2005.
Vice President-Clinical Development at Anesiva, Inc. from 2002 to 2005.
Vice President-Clinical Development at Pro-Duct Health, Inc. from 2000 to 2001.
Faculty Member at the University of California San Diego from 1992 to 1996.
Chief Medical Officer & Senior Vice President at Medivation LLC (California) from 2009 to 2015.
Vice President-Clinical Development at Cytyc Health Corp.
from 2001 to 2002.
Vice President-Clinical Development at Corgentech, Inc. in 2005.
Chief Resident-Internal Medicine at Yale School of Medicine.
Education includes undergraduate degree from the University of Oklahoma in 1981 and doctorate from the University of Oklahoma College of Medicine in 1985.